Compare · DFTX vs XXII
DFTX vs XXII
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and 22nd Century Group Inc. (XXII): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and XXII operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.51B, about 7.6x XXII ($332.0M).
- Over the past year, DFTX is up 196.5% and XXII is down 99.8% - DFTX leads by 296.2 points.
- DFTX has been more active in the news (3 items in the past 4 weeks vs 2 for XXII).
- Both have 4 recent analyst ratings on file.
- Company
- Definium Therapeutics Inc.
- 22nd Century Group Inc.
- Price
- $23.02-2.29%
- $0.52+9.16%
- Market cap
- $2.51B
- $332.0M
- 1M return
- -0.95%
- -27.02%
- 1Y return
- +196.46%
- -99.79%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- AMEX
- IPO
- News (4w)
- 3
- 2
- Recent ratings
- 4
- 4
22nd Century Group Inc.
22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest XXII
- 22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes
- 22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers
- 22nd Century Group (Nasdaq: XXII) Ignites Major VLN® Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand
- 22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review
- SEC Form 10-Q filed by 22nd Century Group Inc.
- 22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 22nd Century Group Reports First Quarter 2026 Financial Results
- 22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026
- 22nd Century Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by 22nd Century Group Inc.